Arun Sanyal, MD, from Virginia Commonwealth University, talks about how to make progress in the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. He recently spoke about this topic at the 21st Annual Harvard Nutrition and Obesity Symposium on NAFLD.
He discusses his session titled “The Microbiome and Fatty Liver Disease,” which he presented at Harvard’s Nonalcoholic Fatty Liver Disease (NAFLD): Mechanisms and Novel Therapeutics symposium.
He talks about the treatment options that are available for treating nonalcoholic fatty liver disease via metabolic pathways. He recently spoke about this topic at the 21st Annual Harvard Nutrition and Obesity Symposium on NAFLD.
He talks about how and why metabolic pathways are targeted when treating nonalcoholic fatty liver disease. He recently spoke about this topic at the 21st Annual Harvard Nutrition and Obesity Symposium on NAFLD.
Preliminary results of the PROMISE trial highlight the relationship between nonalcoholic fatty liver disease and cardiovascular disease, which has been debated previously.
For her session at the 21st Annual Harvard Nutrition and Obesity Symposium on NAFLD, Kathleen Corey, MD, MPH, MMSc, highlighted her research on the connection between NAFLD and cardiovascular disease.
Nonalcoholic steatohepatitis is a potentially progressive form of nonalcoholic fatty liver disease. Recent research, which was discussed at the 21st Annual Harvard Nutrition and Obesity Symposium on NAFLD, shows an increasing burden of these diseases worldwide. Speaker Zobair Younossi, MD, from Inova Fairfax Medical Campus, shed light.